CD4+Foxp3+ Regulatory T-cell Impairment by Paclitaxel is Independent of Toll-like Receptor 4

Scandinavian Journal of Immunology

Volumn 73, Issue 4, 2011, Pages 301-308

  Zhu, Y ^a   Liu, N ^a   Xiong, S D ^a   Zheng, Y J ^a   Chu, Y W ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; PACLITAXEL; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CYTOKINE PRODUCTION; EFFECTOR CELL; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOMA, LEWIS LUNG; CELL COUNT; CELL SURVIVAL; CYTOKINES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PACLITAXEL; SPLEEN; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY; TOLL-LIKE RECEPTOR 4;

EID: 79952056158     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2011.02514.x     Document Type: Article

References (23)

1. Miller ML, Ojima I. Chemistry and chemical biology of taxane anticancer agents. Chem Rec 2001;1:195-211.
2. Scripture CD, Figg WD, Sparreboom A. Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy. Ther Clin Risk Manag 2005;1:107-14.
3. Ding AH, Porteu F, Sanchez E, Nathan CF. Shared actions of endotoxin and taxol on TNF receptors and TNF release. Science 1990;248:370-2.
4. Kawasaki K, Akashi S, Shimazu R et al. Mouse toll-like receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by Taxol. J Biol Chem 2000;275:2251-4.
5. Xu D, Liu H, Komai-Koma M. Direct and indirect role of toll-like receptors in T cell mediated immunity. Cell Mol Immunol 2004;1:239-46.
6. Komai-Koma M, Jones L, Ogg GS, Xu D, Liew FY. TLR2 is expressed on activated T cells as a costimulatory receptor. Proc Natl Acad Sci USA 2004;101:3029-34.
7. Matsuguchi T, Takagi K, Musikacharoen T, Yoshikai Y. Gene expressions of lipopolysaccharide receptors, toll-like receptors 2 and 4, are differently regulated in mouse T lymphocytes. Blood 2000;95:1378-85.
8. Takahashi T, Sakaguchi S. Naturally arising CD25+CD4+ regulatory T cells in maintaining immunologic self-tolerance and preventing autoimmune disease. Curr Mol Med 2003;3:693-706.
9. Byrd-Leifer CA, Block EF, Takeda K, Akira S, Ding A. The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol. Eur J Immunol 2001;31:2448-57.
10. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003;299:1033-6.
11. Chu Y, Wang LX, Yang G et al. Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma. J Immunother 2006;29:367-80.
12. Sundstedt A, Celander M, Ohman MW, Forsberg G, Hedlund G. Immunotherapy with tumor-targeted superantigens (TTS) in combination with docetaxel results in synergistic anti-tumor effects. Int Immunopharmacol 2009;9:1063-70.
13. Yu B, Kusmartsev S, Cheng F et al. Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer. Clin Cancer Res 2003;9:285-94.
14. Eralp Y, Wang X, Wang JP et al. Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Breast Cancer Res 2004;6:275-63.
15. Zhang L, Dermawan K, Jin M et al. Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy. Clin Immunol 2008;129:219-29.
16. Gelman AE, Zhang J, Choi Y, Turka LA. Toll-like receptor ligands directly promote activated CD4+ T cell survival. J Immunol 2004;172:6065-73.
17. Sutmuller RP, den Brok MH, Kramer M et al. Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest 2006;116:485-94.
18. Chen Q, Davidson TS, Huter EN, Shevach EM. Engagement of TLR2 does not reverse the suppressor function of mouse regulatory T cells, but promotes their survival. J Immunol 2009;183:4458-66.
19. Oberg H, Ly T, Ussat S et al. Differential but direct abolishment of human regulatory T cell suppressive capacity by various TLR2 ligands. J Immunol 2010;184:4733-40.
20. Crellin NK, Garcia RV, Hadisfar O et al. Human CD4+ T cells express TLR5 capacity and expression of FOXP3 in CD4+CD25+ T regulatory cells. J Immunol 2005;175:8051-9.
21. Peng GY, Guo Z, Kiniwa Y et al. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 2005;309:1380-4.
22. Caramalho I, Lopes-Carvalho T, Ostler D et al. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J Exp Med 2003;197:403-11.
23. Ausubel F. Are innate immune signaling pathways in plants and animals conserved? Nat Immunol 2005;6:973-9.